Key Takeaways
- The First Trust NYSE Arca Biotechnology ETF (FBT) offers broad exposure to the biotechnology sector, with over $2.86 billion in assets.
- FBT has a 0.55% expense ratio and a year-to-date return of approximately 27%.
- Investors can explore alternatives like iShares Biotechnology ETF and State Street SPDR S&P Biotech ETF for different risk and cost profiles.
Overview of Smart Beta ETFs
The First Trust NYSE Arca Biotechnology ETF (FBT), launched on June 19, 2006, focuses on the health care sector, specifically biotechnology. It is categorized as a smart beta ETF, distinct from traditional market cap weighted indexes that simply reflect market performance. Smart beta strategies aim to outperform the market through selective stock picks based on fundamental characteristics, although not all strategies guarantee superior results.
Fund Management and Index
Managed by First Trust Advisors, FBT seeks to mirror the NYSE Arca Biotechnology Index, which is an equal-dollar weighted index representing various biotechnology firms. This ETF has grown to manage assets exceeding $2.86 billion, making it one of the larger options in its category.
Cost Considerations
Expense ratios significantly influence an ETF’s total return. FBT has an annual operating expense of 0.55%, aligning with its peers, but no dividend yield to report. These factors are essential for evaluating long-term investment viability.
Sector Focus and Holdings
FBT’s portfolio is fully allocated to the healthcare sector, providing diversified exposure to mitigate single stock risk. Transparency allows investors to review daily holding disclosures. Its top holdings include Halozyme Therapeutics, Corcept Therapeutics, and Natera, making up nearly 38% of total assets.
Performance and Risk Analysis
As of September 11, 2026, FBT has delivered a year-to-date return of around 27% and a 12-month return of approximately 50.41%. The fund exhibits a beta of 0.67 and a standard deviation of 20.72% over the past three years, indicating a higher level of risk with approximately 31 concentrated holdings.
Investment Alternatives
For those interested in biotechnology, FBT presents an attractive option; however, alternatives like the iShares Biotechnology ETF (IBB) and the State Street SPDR S&P Biotech ETF (XBI) offer different expense ratios and asset strengths. IBB charges 0.44%, while XBI is even lower at 0.35%. Investors seeking lower-cost or less risky options may consider these traditional market cap weighted ETFs.
The content above is a summary. For more details, see the source article.